首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   117129篇
  免费   6134篇
  国内免费   142篇
耳鼻咽喉   1776篇
儿科学   5247篇
妇产科学   4026篇
基础医学   16228篇
口腔科学   2844篇
临床医学   8383篇
内科学   22177篇
皮肤病学   3406篇
神经病学   9010篇
特种医学   5141篇
外国民族医学   32篇
外科学   19225篇
综合类   1602篇
一般理论   31篇
预防医学   5865篇
眼科学   3405篇
药学   8078篇
中国医学   323篇
肿瘤学   6606篇
  2018年   923篇
  2017年   787篇
  2016年   1106篇
  2015年   1238篇
  2014年   1623篇
  2013年   2394篇
  2012年   3154篇
  2011年   3184篇
  2010年   1993篇
  2009年   1964篇
  2008年   3291篇
  2007年   3531篇
  2006年   3670篇
  2005年   3799篇
  2004年   3738篇
  2003年   3603篇
  2002年   3556篇
  2001年   7059篇
  2000年   7005篇
  1999年   5896篇
  1998年   1634篇
  1997年   1579篇
  1996年   1348篇
  1995年   1214篇
  1994年   1105篇
  1993年   1135篇
  1992年   3792篇
  1991年   3601篇
  1990年   3584篇
  1989年   3388篇
  1988年   3009篇
  1987年   2914篇
  1986年   2822篇
  1985年   2648篇
  1984年   1965篇
  1983年   1603篇
  1982年   936篇
  1981年   921篇
  1980年   775篇
  1979年   1834篇
  1978年   1355篇
  1977年   1123篇
  1976年   949篇
  1975年   1200篇
  1974年   1230篇
  1973年   1204篇
  1972年   1045篇
  1971年   980篇
  1970年   887篇
  1969年   799篇
排序方式: 共有10000条查询结果,搜索用时 562 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
Hillermann  T.  Homburg  K.  Rainer  M.  Budde  U. 《Der Anaesthesist》2022,71(4):299-302
Die Anaesthesiologie - Eine junge Patientin erleidet während der Anlage einer axillären Plexusblockade einen generalisierten Krampfanfall. Die Mechanismen, im Wesentlichen die vermutlich...  相似文献   
9.

Objective

Low psoas muscle area is shown to be an indicator for worse postoperative outcome in patients undergoing vascular surgical. Additionally, it has been associated with longer durations of hospital stay in patients with cancer who undergo surgery and subsequently greater health care costs in Europe and the United States. We sought to evaluate this effect on hospital expenditure for patients undergoing vascular repair in a health care system with universal access.

Methods

Skeletal muscle mass was assessed on preoperative abdominal computed tomography scans of patients undergoing open aortic aneurysm repair in a retrospective fashion. The skeletal muscle index (SMI) was used to define low muscle mass. Health care costs were obtained for all patients and the relationship between a low SMI and higher costs was explored using linear regression and cross-sectional analysis.

Results

We included 156 patients (81.5% male) with a median age of 72 years undergoing elective surgery for infrarenal abdominal aortic aneurysm in this analysis. The median SMI for patients with low skeletal muscle mass was 53.21 cm2/kg and for patients without, 70.07 cm2/kg. Hospital duration of stay was 2 days longer in patients with low skeletal muscle mass as compared with patients with normal (14 days vs 11 days; P = .001), as was duration of intensive care stay (3 days vs 1 day; P = .01). The median overall hospital costs were €10,460 higher for patients with a low SMI as compared with patients with a normal physical constitution (€53,739 [interquartile range, €45,007-€62,471] vs €43,279 [interquartile range, €39,509-€47,049]; P = .001). After confounder adjustment, a low SMI was associated with a 14.68% cost increase in overall hospital costs, for a cost increase of €6521.

Conclusions

Low skeletal muscle mass is independently associated with higher hospital as well as intensive care costs in patients undergoing elective aortic aneurysm repair. Strategies to reduce this risk factor are warranted for these patients.  相似文献   
10.

Introduction

In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.

Methods

Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.

Results

Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.

Conclusions

These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号